#USA #New York #investors #Faruqi & Faruqi #Skye Bioscience

Overview of the Investigation

Faruqi & Faruqi, LLP, a prominent national law firm specializing in securities litigation, is currently investigating claims against Skye Biosciences, Inc. This action comes in response to allegations that the company and its executives made misleading statements regarding its clinical product, nimacimab. Investors who purchased Skye's securities between November 2024 and October 2025 may have grounds for legal recourse due to these assertions.

Background on Skye Biosciences

Skye Biosciences, listed on the NYSE under the ticker SKYE, focuses on the development of cannabinoid-based therapies. Despite its innovative approach, recent press releases have suggested that the efficacy of nimacimab has been overstated. This drug, marketed as a breakthrough in the treatment field, has failed to meet significant clinical endpoints, leading to hefty losses for investors.

Details of the Allegations

A press release dated October 6, 2025, announced disheartening results from Skye's Phase 2a clinical trials, revealing that nimacimab did not achieve the primary endpoint of weight loss compared to a placebo. The announcement was a significant blow to investor confidence, resulting in a 60% drop in stock price—from $4.75 to $1.90 per share—within hours of the news.
The allegations further suggest that the firm misled investors regarding nimacimab's effectiveness, misrepresenting its clinical and commercial prospects. As detailed in the investigations, such misleading statements can constitute serious violations under federal securities laws.

Investor Options and Next Steps

Faruqi & Faruqi is urging affected investors to reach out to discuss their legal rights. Those impacted by the decline in Skye's stock value are encouraged to consider applying to be lead plaintiffs in a class-action lawsuit that has been initiated against the company. This is an opportunity for investors to take an active role in the legal proceedings surrounding Skye Biosciences.

The deadline to seek the lead plaintiff role is set for January 16, 2026. Investors are advised to contact Faruqi & Faruqi directly to explore their options and potentially recover losses from investments made during the specified period. For further information, interested parties can visit the law firm’s dedicated page or reach them via phone at 877-247-4292.

Conclusion

The situation with Skye Biosciences highlights the critical need for transparency and accountability in financial disclosures. As investigations unfold, investors are encouraged to remain informed and proactive regarding their legal standing. Faruqi & Faruqi, LLP remains dedicated to supporting the rights of investors impacted by corporate misconduct, ensuring that they have the necessary avenues to seek redress.